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Abstract   
 
Background: There is great interest in widening the use of high sensitivity cardiac troponins for 
population cardiovascular disease (CVD) and heart failure screening.  However, it is not clear 
whether cardiac troponin T (cTnT) and troponin I (cTnI) are equivalent measures of risk in this 
setting.  We aimed to compare and contrast i) the association of cTnT and cTnI with CVD and 
non-CVD outcomes, and ii) their determinants in a Genome wide association study (GWAS). 
Methods: High-sensitivity cTnT and cTnI were measured in serum from 19,501 individuals in 
Generation Scotland Scottish Family Health Study. Median follow-up was 7.8 years (Q1-Q3 7.1-
9.2). Associations of each troponin with a composite CVD outcome (1,177 events), CVD death 
(n=266), non-CVD death (n=374), and heart failure (n=216) were determined using Cox models. 
A genome-wide association study was conducted using a standard approach developed for the 
cohort. 
Results: Both cTnI and cTnT were strongly associated with CVD risk in unadjusted models. 
After adjusting for classical risk factors, the hazard ratio for a one standard deviation increase in 
log transformed troponin was 1.24 (95%CI 1.17-1.32) and 1.11 (1.04-1.19) for cTnI and cTnT, 
respectively; ratio of HRs 1.12 (1.04-1.21). cTnI, but not cTnT, was associated with MI and 
CHD. Both cTnI and cTnT had strong associations with CVD death and heart failure. By 
contrast, cTnT, but not cTnI, was associated with non-CVD death; ratio of HRs 0.77 (0.67-0.88). 
We identified five loci (53 individual SNPs) that had GWAS significant associations with cTnI, 
and a different set of four loci (4 SNPs) for cTnT. 
Conclusions: The upstream genetic causes of low grade elevations in cTnI and cTnT appear 
distinct, and their associations with outcomes also differ. Elevations in cTnI are more strongly 
associated with some CVD outcomes, whereas cTnT is more strongly associated with the risk of 
non-CVD death.  These findings help inform selection of an optimal troponin assay for future 
clinical care and research in this setting.   
 
Key Words: Cardiovascular disease risk factors; genetics; troponin; troponin T 
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Clinical Perspective 
 
What is new? 
• High sensitivity cardiac troponin I and troponin T have different associations with health 
outcomes, including specific CVD outcomes, in the general population. 
• Upstream genetic causes of elevated cardiac troponin I and troponin T in healthy people 
also appear distinct from each other. 
 
What are the clinical implications? 
• Cardiac troponin I appears to be a more specific marker of risk of composite CVD and 
coronary heart disease, while cardiac troponin T is more strongly associated with risk of 
non-CVD death. 
• Both cardiac troponin I and cardiac troponin T were associated with HF and CVD death. 
• These findings help inform selection of an optimal troponin assay for future clinical care 
and research in the general population.   
D
ow
nloaded from
 http://ahajournals.org by on May 9, 2019
10.1161/CIRCULATIONAHA.118.038529 
4 
Introduction 
The 99th centile of high sensitivity cardiac troponin T (cTnT) and troponin I (cTnI), derived from 
a normal reference population, is used to detect myocardial necrosis as part of a diagnosis of 
myocardial infarction 1,2. However, low grade elevations in troponin in the general population, 
well below the diagnostic threshold, are also associated with future cardiovascular disease 
(CVD) events and may have a role in screening the general population for CVD risk 3,4.  
 In existing cohort studies, high sensitivity cTnI or cTnT are frequently measured 
individually without an evidence-based decision as to which biomarker might be preferable to 
achieve a specific aim. This is reflected in a recent study level meta-analysis where thirteen 
studies measured cTnI and seven studies measured cTnT, although none measured both 4. One 
study has compared the performance different cTnI assays in the general population 5. Our own 
recent data highlight differential cross-sectional associations of cTnI and cTnT with classical 
CVD risk factors, and their relatively weak association with each other in a general population 6. 
Therefore, there is a need for a systematic approach to compare high sensitivity cTnI and cTnT 
and their associations with a range of CVD and non-CVD health outcomes. Such a study has the 
potential to prioritise which of these assays should be used to improve CVD risk prediction, and 
for future measurement in established biobanks. 
 As a separate issue, the causal upstream determinants of troponin elevation in the general 
population are not clear. The use of genetic variants to investigate potential causal pathways is 
now well established 7. A genome wide association study (GWAS) of 11,544 individuals has 
been reported for cTnT 8, but there is currently limited data reported on genetic determinants of 
either troponin. Contrasting the upstream genetic determinants of low grade elevations in cTnI 
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and cTnT would allow further mechanistic insight into potential differences in their causal 
determinants. 
 Using clinical high sensitivity assays, we measured both cTnT and cTnI in 19,501 
individuals in the Generation Scotland Scottish Family Health Study (GS:SFHS). We aimed to 
contrast the associations of cTnI and cTnT with risk of CVD and non-CVD health outcomes, and 
to conduct a GWAS for both of the biomarkers to investigate differences in both the causes and 
consequences of their elevation. 
 
Methods 
The data, analytic methods, and study materials will be made available to other researchers for 
purposes of reproducing the results or replicating the procedure subject to a successful project 
application to the Generation Scotland Access Committee, and requisite associated ethical 
approval for access to linked health data from NHS Scotland. 
Study recruitment 
The recruitment and design of GS:SFHS has been reported elsewhere 9,10. During 2006-2010 
potential participants (aged 35-65 years) were identified and invited at random from 
collaborating general medical practices in Scotland.  Participants were asked to identify ≥one 
first-degree relative aged ≥18 years who would also be able to participate. Subsequently, 21,476 
participants aged between 18 and 98 years attended a staffed research clinic in Scotland. 
Participants completed a health questionnaire, and had physical and clinical characteristics 
measured according to a standardised protocol 10.  Past medical history, including a diagnosis of 
diabetes mellitus (type 1 or type 2) and cardiovascular disease (prior myocardial infarction or 
stroke), and use of medications was self-reported. Family history of CVD was defined as a self-
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report of parents or siblings having heart disease or stroke. Fasting blood samples were taken, 
according to a standard operating procedure, and serum samples were separated. Baseline 
biochemistry including total cholesterol, HDL cholesterol, and serum creatinine, were measured 
at the time of collection and additional serum aliquots were stored at -80oC for future 
biochemical analyses. Scottish Index of Multiple Deprivation (SIMD) scores, nationally 
compiled composite measures of small-area deprivation, were derived from participant postcodes 
11. The study obtained written informed consent from all participants and  received ethical 
approval from the National Health Service Tayside Committee on Medical Research Ethics 
(REC Reference Number: 05/S1401/89). 
Measurement of high sensitivity troponins 
High sensitivity cTnT (Roche Diagnostics, Basel, Switzerland) and high sensitivity cTnI 
(ARCHITECT STAT, Abbott Laboratories, Abbott Park, IL, Abbott Diagnostics) were measured 
on Cobas e411 and i1000SR analysers respectively, using the manufacturers calibrators and 
quality controls 6. We also participated in the UK National External Quality Assurance Scheme 
for these biomarkers during the conduct of study. The limit of blank (LoB) of the cTnT assay is 
set to 3ng/L by the manufacturer, while we reported anything less than 1.2ng/L for cTnI as below 
the limit of blank 12. Results below the LoB (“undetectable”) are reported as half of the limit of 
blank (i.e. 1.5ng/L for cTnT and 0.6ng/L for cTnI) for continuous analyses. A total of 19,501 
individuals provided measurements of both troponins. 
Health outcomes 
Participants were followed to the end of September 2017 for deaths or hospitalisations for events 
of interest. Outcomes were identified using a national database: the Information Services 
Division National Health Service record linkage for Scotland. This contains information on 
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Scotland’s morbidity records for acute specialty day case and inpatient discharges from hospital 
(Scotland’s morbidity record [SMR] 01) since January 1981. Causes of death, derived from 
death certificates, were obtained from National Health Service Central. For this study, the 
primary composite CVD outcome was any event included in the national ASSIGN risk score 
definition of CVD 13, including any ICD-10 codes I20-25, G45, I60-69, as well as death from 
CVD (I00-I99), and OPCS4 procedure codes L29.5, L31.1, K40-46, K49, and K75 (procedures 
comprising carotid endarterectomy, carotid angioplasty, coronary artery bypass graft, and 
percutaneous transluminal coronary angioplasty). CVD death included deaths coded from 
underlying causes I00-I99; all others were classified as non-CVD deaths. Other clinical 
outcomes (fatal or non-fatal) included coronary heart disease (I00-I25), myocardial infarction 
(I21, I22), ischaemic stroke (I63, I64, G45), any malignancy (C00-C97), and hospitalisation for 
heart failure (I50, I42.0, I42.6, I42.7, I42.9, I11.0). 
GWAS 
Details on blood collection and DNA extraction are provided elsewhere 14. Samples were 
genotyped using the Illumina Human OmniExpressExome-8v1.0 Bead Chip and Infinum 
chemistry and processed using the Illumina Genome Studio Analysis software v2011 (Illumina, 
San Diego, CA, USA). Quality control was performed to remove SNPs with <98% call rate, 
individuals with a genotyping rate <98% and SNPs with a Hardy Weinberg equilibrium test p-
value ≤1 ×10−6 and a minor allele count of <50. Individuals who were identified as population 
outliers through principal component analyses of their genotypic information were also removed 
15. Following quality control there were 19,904 GS:SFHS individuals (11,731 females and 8173 
males) that had genotypic information for 561,125 autosomal SNPs, with 19,130 participants 
having phenotyping for at least one troponin .In order to increase the density of variants 
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throughout the genome, the genotyped data were imputed utilising the Sanger Imputation Service 
(https://imputation.sanger.ac.uk/) using the HRC panel v1.1 16. Autosomal haplotypes were 
checked to ensure consistency with the reference panel (strand orientation, reference allele, 
position) then pre-phased using Shapeit2 v2r837 17,18 the Shapeit2 duohmm option11 19, taking 
advantage of the cohort family structure in order to improve the imputation quality. Monogenic 
and low imputation quality (INFO < 0.4) variants were removed from the imputed dataset 
leaving 24,111,857 variants available for downstream analysis. 
Statistical analysis for risk associations 
The intra-class correlation coefficients for cTnT and cTnI were 0.18 (95%CI 0.16, 0.19) and 0.09 
(95%CI 0.07, 0.10) respectively, for clustering within family groups. Allowing for familial 
clustering had no appreciable effect on any analyses, so the results presented here are from 
analyses without adjustment for clustering. Multiple imputation by chained equations (MICE) 
was used to account for missing data for classical risk factors (but not missing troponin 
concentrations) in regression models. Ten imputed datasets were used. 
 To illustrate associations of troponins and classical risk factors with health outcomes, 
available complete data were presented using categorical variables expressed as frequencies and 
percentages, and continuous variables as medians (interquartile interval) or mean (standard 
deviation). Each troponin was split into three unequal groups (low; cTnT <3.0ng/L & cTnI 
≤1.8ng/L, intermediate; cTnT 3.0-5.7ng/L & cTnI 1.9-3.0ng/L, high cTnT ≥5.8ng/L & cTnI 
≥3.1ng/L, so that the proportion within each grouping was similar for each troponin. Kaplan 
Meier curves were used to illustrate the association of the three groups of each troponin with 
incident CVD. 
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 Unadjusted and adjusted (for age, sex, total cholesterol, HDL-cholesterol, systolic blood 
pressure, number of cigarettes smoked per day, rheumatoid arthritis, diabetes, SIMD, family 
history of CVD, cholesterol lowering medication, blood pressure lowering medication and 
baseline CVD). Cox proportional hazards models were used to investigate the association of the 
troponins with health outcomes. Further adjustment for BMI and creatinine made no substantial 
difference (data not shown). The shapes of the associations were tested and illustrated using 
restricted cubic splines (knots at 2,3,5,10, and 25pg/ml for cTnI, and at 3.3, 5, 8, 10, and 25pg/ml 
for cTnT) and also modelled using troponins as continuous risk factors (per 1 standard deviation 
increase after log-transformation). The proportional hazards assumption was tested by plotting 
Schoenfeld residuals. Tests for interaction of cTnT and cTnI with CVD events were also 
conducted by baseline classical risk factors. The 95% CI for the difference in the log hazard ratio 
for cTnI and cTnT was obtained by bootstrapping (5000 times); exponentiation of the difference 
in the log hazard ratios gives the ratio of the hazard ratios. Improvement in the clinical prediction 
of primary CVD (using age, sex, total cholesterol, HDL cholesterol, systolic blood pressure, 
number of cigarettes per day, SIMD, diabetes, family history of CVD, and rheumatoid arthritis) 
on addition of each troponin individually was tested (in participants without baseline CVD and 
aged ≥40 years) using the continuous net reclassification index and integrated discrimination 
index. These tests were conducted using the nricens package (R) with 5000 bootstraps. All 
analyses were performed in STATA (version 14.2) and R (version 3.3.1). 
Statistical analysis for GWAS 
GS:SFHS has previously been used in a variety of GWAS studies and the imputed data is 
research ready 20,21. There were 19,130 individuals with a troponin result and quality-controlled 
genomic data.  
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 Genome-wide associations were performed on HRC-imputed data, only results from 
variants with a minor allele count of 50 in our sample. For each phenotype, an additive model for 
the fitted SNP fixed effect was set up incorporating age and sex as covariates and a random 
polygenic effect accounting for relatedness among participants. Phenotypes were inverse-normal 
transformed to ensure a normal distribution of the model’s residuals, using the ‘rntransform’ 
function in the GenABEL R package 22. Associations with the HRC imputed variants were 
performed with the software RegScan v0.2 23. The pgresidualY estimated from the polygenic 
function in GenABEL was used for association analysis. The effect size, standard errors and p 
values were thereafter corrected to account for relatedness using the GRAMMAR-Gamma 
factors also provided by the ‘polygenic’ function 24. The ‘polygenic’ command in the GenABEL 
R package was used to calculate Genetic kinship-based heritability. The standard errors of 
heritability estimates were obtained by re-running the ‘polygenic’ command and fixing the 
heritability to 0. 
 GWAS significance of SNPs is attained at a p-value of <5X10-8, and suggestive hits at p-
value <1X10-5. Manhattan plots are used to illustrate hits using these thresholds. All suggestive 
hits for both troponins were read into FUMA 25 (http://fuma.ctglab.nl/snp2gene) to identify loci 
of interest and functional annotations. The 1000 genomes European reference panel (phase 3) 
was used to account for LD in the sample. For the primary analyses, we focused only on SNPs 
that attained a GWAS significant association, with a further sensitivity analysis using a more 
relaxed criteria for exploration; the minimum value of a lead SNP was taken at a p-value of 
<5X10-7, and without a minimum minor allele frequency, to maximise loci identification. 
However, interpretation of results in this sensitivity analysis should place less emphasis on rare 
isolated variants  
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Results 
Crude associations of troponins with classical risk factors and with CVD  
Detectable concentrations of cTnI and cTnT were found in 14579 participants (74.8%) and 
10395 participants (53.3%) respectively. Both troponins were generally associated with adverse 
classical CVD risk factors, with the exception that cTnI and cTnT were inversely associated with 
current smoking, and cTnT was inversely associated with total cholesterol (supplemental table 
1). The Spearman correlation coefficient between cTnT and cTnI was r=0.443 (p<0.001). 
 Median follow-up was 7.8 years (Q1-Q3 7.1-9.2) for the primary composite CVD 
endpoint. Of the 19,501 participants 1,177 experienced an incident CVD during follow-up 
(6.0%), 640 participants died (3.3%), and 266 died from CVD causes (1.4%). Participants who 
experienced the composite CVD outcome generally had a more adverse risk factor profile 
including being older, more frequently being male, having a higher BMI, higher blood pressure, 
lower HDL-cholesterol (but also a lower total cholesterol), a higher deprivation score, were more 
frequently smokers, and were more likely to have baseline CVD, diabetes or rheumatoid arthritis, 
or to be taking cholesterol or blood pressure lowering medication (Table 1). Those who 
experienced a composite CVD event had almost a 2-fold higher median baseline cTnI and cTnT 
(Table 1). Similar results were found for other outcomes of interest; both troponins were higher 
in those who experienced every adverse outcome of interest (supplemental tables 2-9). Kaplan 
Meier curves show that both cTnI and cTnT were associated with the probability of CVD-free 
survival (both log rank tests p<0.001) (supplemental figure 1). 
Shape of the association of troponins with outcomes 
Using undetectable levels of each troponin as the referent, the association of elevated troponin 
with composite CVD was explored by restricted cubic splines (Fig 1). For both cTnI and cTnT 
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there was a rapid rise in risk in unadjusted models. For instance at a cTnI level of 5ng/L the HR 
was 7.7 (95% CI 6.3-9.3), compared to undetectable cTnI, and at 20ng/L was 12.8 (9.9-16.5). 
The corresponding HRs for cTnT were 2.2 (1.9-2.7) and 12.2 (10.1-14.9), respectively. For both 
troponins, there was a levelling off in increasing risk at higher levels of troponin. Adjustment for 
classical risk factors attenuated the associations for both troponins substantially, and made the 
associations more linear. In the adjusted model, at values of 5ng/ml and 20ng/L, the HRs were 
1.5 (1.2-1.9) and 2.6 (1.9-3.4) for cTnI, and 0.97 (0.80-1.17) and 1.4 (1.1-1.8) for cTnT, 
respectively. The associations of both troponins with CVD death was more pronounced 
(supplemental figure 2). Only cTnT showed trends towards a positive relationship with non-
CVD death in adjusted models (supplemental figure 3) and therefore had stronger associations 
with all cause mortality (supplemental figure 4). Only cTnI, not cTnT, was associated with MI 
and CHD (supplemental figure 5 & 6), and adjustment for age and sex alone was sufficient to 
ameliorate the association between cTnT and MI or CHD (data not shown). Both cTnI and cTnT 
were associated with ischaemic stroke and heart failure (supplemental figure 7 & 8). After 
adjustment, neither troponin was associated with cancer (supplemental figure 9). 
 A higher category (low/intermediate/high) of cTnI was associated with increased 
unadjusted rate of composite CVD within each category of cTnT (Fig 2). Likewise, a higher 
category of cTnT was associated with increased rate of composite CVD within each category of 
cTnI (Fig 2). After controlling for cTnT, each category increase in cTnI had a HR of 1.92 
(95%CI 1.77-2.07) for composite CVD compared to the preceding category. After controlling for 
cTnI, the HR for one category increase in cTnT was 1.64 (95%CI 1.52-1.78).   
Comparison of the association of cTnI and cTnT with outcomes 
We then compared the extent of the adjusted association of cTnI and cTnT with the different 
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outcomes. One standard deviation increase in log cTnI was associated with a HR of 1.24 for 
composite CVD, whereas the HR was 1.11 for one standard deviation increase in log cTnT. The 
ratio of these hazard ratios indicates the association with composite CVD was stronger for cTnI: 
1.12 (95%CI 1.04-1.21) (Table 2). Both troponins had similarly strong associations with CVD 
death, and both had stronger associations with CVD death than for the composite CVD outcome 
(Table 2). Both troponins were also strongly associated with heart failure (Table 2). cTnT, but 
not cTnI, had an association with non-CVD death (ratio of HRs 0.77 (95% CI 0.67-0.88)), and 
consequently cTnT also had a stronger association with all cause death than cTnI (Table 2). In 
contrast, only cTnI was associated with MI or CHD; cTnT showed no association with either 
outcome. Both troponins showed an association with ischaemic stroke, and neither were 
associated with incident cancer after adjustment (Table 2). When both cTnI and cTnT were 
included in the same adjusted model together, only cTnI remained associated with the composite 
CVD outcome (Table 3). 
Interaction by classical risk factors 
Investigating interactions by baseline risk factors for the composite CVD outcome, both cTnI 
and cTnT showed trends to be less strongly associated with composite CVD among those with 
baseline CVD or taking blood pressure or cholesterol lowering medications (supplemental figure 
10). cTnI was more strongly associated with composite CVD risk among patients with diabetes 
(p for interaction 0.009) (supplemental figure 10). There were no other notable interactions. 
Primary composite CVD prediction models 
Using the continuous net reclassification index, a clinical prediction model in those without 
baseline CVD and aged ≥40years (n=12,496) was improved by the addition of cTnI which 
yielded a continuous net reclassification index improvement of 7.7% (95%CI 2.8%, 11.7%; 
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p=0.004), and an integrated discrimination index of +0.005 (95%CI 0.002, 0.009; p<0.001). The 
clinical prediction model also showed a trend to be improved by addition of cTnT separately, 
yielding a continuous net reclassification index improvement of 8.0% (95%CI -2.3%, 11.9%; 
p=0.064), and an integrated discrimination index of +0.001 (95%CI 0.000, 0.002; p=0.001). 
GWAS for cTnI and cTnT 
Heritability of cTnI was 0.249±0.013 and cTnT was 0.35±0.011. There were 5 loci for cTnI that 
reached genome wide significance (Fig 3a). These included SNPs at KLKB1 (4q35.2: 23 SNPS at 
GWAS significance), VCL/AP3M1/ADK (10q22.2: 2 SNPs), ANO5 (11p14.3: 14 SNPs), 
CEP95/SMURF2 (17q23.3: 3 SNPs), and LMAN1/CPLX4 (18q21.32: 11 SNPs) genes (Table 4). 
There was an isolated intergenic SNP in chromosome 1 that was of borderline genome wide 
significance, flanking a suggestive hit for DAB1 (1p32.1) SNP. There were marked differences in 
the GWAS Manhattan plot for cTnT compared to cTnI (Fig 3b), with limited overlap of 
associated loci, and far fewer suggestive loci associated with cTnT in general. There were 
isolated low frequency SNPs at the genes of C1orf112, TRABD2A (2p11.2), SORBS2 (4q35.1), 
and PTPRD (9p23) for cTnT (Table 4).  
 Using a more relaxed threshold for statistical significance identified other loci of 
potential interest. For cTnI, a locus at F12/GRK6 (5q35.3: 5SNPs) also showed suggestive trends 
towards association (Supplemental table 10). For cTnT there was also a suggestive hit for a locus 
at POC1B (12q21.33: 16 SNPs), and TMEM131/ZAP70 (2q11.1: 4 SNPs). Excluding those with 
baseline CVD had minimal impact on the primary genetic associations (Supplemental table 11). 
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Discussion 
This study highlights several important findings that are relevant to potential future clinical use 
of high sensitivity troponins in CVD risk prediction, and also relevant to scientific enquiries into 
the aetiology of elevated troponin in apparently healthy people. Most remarkably, we 
demonstrate the striking differences in cTnI and cTnT in terms of their association with 
composite CVD and with specific CVD outcomes. Both have similar strong associations with 
risk of CVD death and heart failure, and both have associations with ischaemic stroke. Most 
surprisingly however, cTnT showed no association with MI or CHD after adjusting for classical 
risk factors; cTnI did. As a result, cTnI was more strongly associated with the primary composite 
CVD outcome. In fact, cTnT showed an association with non-CVD death while cTnI did not. 
These findings suggest different upstream causes of modest elevations in cTnI and cTnT in the 
general population. In line with this, our GWAS highlights little overlap in the genetic 
determinants of circulating cTnI and cTnT. This is in line with our previous report, 
demonstrating differences in the associations of classical risk factors with the troponins in a 
cross-sectional study 6.  
 In a recent study level meta-analysis 4, in the top vs bottom third of the population for 
each troponin, the hazard ratio of CVD was nominally stronger for cTnT than cTnI (HR=1.60 vs 
1.36; p=0.171), and cTnT was more strongly associated with fatal CVD (p=0.027). However, the 
troponins were measured in different cohorts, which limits the ability to make direct 
comparisons. Our study is the first large general population study of which we are aware to 
compare systematically the disease associations of the two troponins directly. 
 The lack of association of cTnT with MI and CHD, after adjusting for classical risk 
factors is unexpected, given that the source of both troponins is cardiac injury. Indeed, previous 
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studies demonstrate that cTnT is associated with LV hypertrophy 26 and coronary plaque count as 
well as plaque phenotype 27,28. The MI and CHD outcomes were associated with cTnT in 
unadjusted models, and with cTnI in adjusted models, so the lack of association is not explained 
by outcome misspecification. Given the additional association of cTnT with fatal-non CVD 
events, it is interesting to speculate what causes cTnT elevation beyond classical risk factors in 
apparently healthy people. cTnT is known to be transiently expressed in foetal skeletal muscle 29 
and it may be possible that non cardiac tissues express cTnT in some circumstances. For 
instance, patients with neuromuscular diseases but with no evidence of heart disease may have 
elevated cTnT, but not an elevated cTnI 30–32. cTnT is also known to be a strong predictor of 
adverse non-cardiac outcome following abdominal surgery 33. As such, different aetiological 
causes of elevations in cTnI and cTnT, and consequently different downstream risks, may be 
sufficient to explain our findings. 
 Upstream genetic determinants of the troponins also appear distinct. For cTnI, the KLKB1 
and F12 genes are both part of the kallikrein-kinin axis and loci have been associated with 
biomarkers of endothelin-1, pro-adrenomedullin 34, B-type natriuretic peptide 35, as well as L-
arginine 36. Given this broad association with vasoactive peptides, it is interesting that the loci 
are associated with cTnI, but no association is seen for cTnT. Plasma prokallikrein is activated 
by active factor XII (encoded by F12) and colocalizes to endothelial cells. Activated kallikrein is 
also involved in procession vasoactive peptides such as bradykinin and renin 37. The loci around 
VCL encode vinculin membrane associated protein, which is perhaps particularly relevant to 
troponin expression, as it appears involved in cytoskeletal modelling in diseased cardiac tissue 
38,39. The anoctamin-5 protein encoded by ANO5 is a poorly characterised chloride channel found 
in skeletal and cardiac muscle, and mutations may be associated with cardiomyopathy 40. Allelic 
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variants of LMAN1 gene are associated with factor V-factor VIII deficiency 41. In contrast, genes 
associated with cTnT include ArgBP2 (SORBS2) which is highly abundant in cardiac z-disc 
structures 42. There is hence a strong biological background for many of these genes being 
associated with cardiac injury or troponin leakage.  
 Strengths of the study include the use of a large and well-phenotyped prospective 
nationwide population study of broadly healthy people, where national record linkage has been 
used for follow-up. Numbers of outcomes lend the study considerable statistical power. The 
direct comparisons of cTnI and cTnT in terms of risk associations in a general population is 
novel, and is supported by the GWAS in a cohort with an established approach to such studies. 
Weaknesses include the family structure of the study, although sensitivity analyses suggest 
family clustering had very limited impact on data in terms of clustering within families. The 
study population is not ethnically diverse, limiting generalisability in that regard, but includes a 
wide age range from participants of both sexes. In common with many electronic health records, 
the small proportion of the population who emigrate from Scotland 43 will not have recorded 
outcomes of interest, but might still be considered “at risk” in our models. This may slightly bias 
estimates, but is unlikely to affect the direct comparison between biomarkers. A large proportion 
of participants had undetectable troponin. This is suboptimal for continuous statistical analyses, 
but we demonstrate results using a number of different models. We also acknowledge that in 
individual patients, as opposed to population studies, accurate measurement of low troponin 
levels would be important in using troponin levels to determine clinical risk. Our observations 
offer limited causal insight as to the reasons underlying differential associations of cTnI and 
cTnT with different outcomes. However, aetiological differences in the upstream causes of 
different troponin elevations are supported by GWAS, and as such our data are sufficient to 
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indicate that care should be taken when selecting a high sensitivity troponin to use as a 
biomarker in general population studies, or as surrogate biomarkers in trials, depending on the 
aims of the study. 
 In conclusion we demonstrate that routine clinical cTnI and cTnT assays have different 
associations with composite cardiovascular, and non-CVD mortality, outcomes in apparently 
healthy people; the cTnI assay is specific for cardiovascular disease risk, whereas the cTnT assay 
is more strongly associated with non-CVD mortality. It also appears that their genetic 
determinants are largely distinct. Future research studies should use this evidence base to select a 
troponin for cohort phenotyping depending on the study aims. This information is also of 
relevance to attempts to improve CVD risk stratification in the population using cardiac troponin 
measurements. 
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Table 1. Association of classical risk factors and Troponin I and Troponin T with composite 
CVD events 
  
No incident CVD 
n=18324 
Incident CVD 
n=1177 
p-value 
Age (years) 46.1±14.61 62.5±11.6 <0.0001 
Male sex 7443 (40.6%) 683 (58.0%) <0.0001 
BMI (kg/m2) 26.6±5.2 28.4±5.1 <0.0001 
SBP (mmHg) 130.7±17.5 140.7±20.2 <0.0001 
Total cholesterol (mmol/L) 5.11±1.07 5.00±1.20 0.0013 
HDL chol (mmol/L) 1.47±0.41 1.34±0.41 <0.0001 
SIMD (score/10) 1.69±1.44 1.96±1.67 <0.0001 
Creatinine 73.3±15.3 81.6±22.3 <0.0001 
Cigarettes per day 2.35±6.75 4.05±9.88 <0.0001 
Current smoking 2829 (16.0%) 227 (20.0%) 0.0003 
Family History of CVD 6953 (38.8%) 451 (38.9%) 0.9095 
Rheumatoid arthritis 262 (1.4%) 52 (4.4%) <0.0001 
Baseline CVD 507 (2.8%) 370 (31.4%) <0.0001 
Baseline diabetes 429 (2.3%) 133 (11.3%) <0.0001 
Cholesterol medications 998 (5.4%) 284 (24.1%) <0.0001 
Blood pressure medication 1276 (7.0%) 298 (25.3%) <0.0001 
hsTnT (ng/L) 3.2 [1.5,5.8] 6.2 [3.2,10.7] <0.0001 
hsTnI (ng/L) 1.8 [0.6,3.0] 3.3 [0.6,5.9] <0.0001 
P-values are from independent sample t-tests for continuous variables with normal distribution  
(i.e. mean ± standard deviation), Mann-Whitney U test for continuous variables with skewed distribution 
(i.e. median [Q1-Q3], or chi squared test for categorical variables (i.e. n (%)) 
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Table 2. Association of troponin I and troponin T (per 1SD increase on the log scale) with risk 
of different events, adjusted for classical risk factors, and the troponins in separate models 
  
Troponin I Troponin T Ratio of the 
hazard ratio* 
(95% CI)  
Hazard ratio 
(95%CI) 
Hazard ratio 
(95%CI) 
 
CVD (n=1177) 1.24 
(1.17 - 1.32) 
1.11 
(1.04 - 1.19) 
1.12  
(1.04-1.12) 
CVD death (n=266) 1.56 
(1.38 - 1.75) 
1.52 
(1.31 - 1.77) 
1.02  
(0.87-1.20) 
Non CVD death (n=374) 1.04 
(0.92 - 1.17) 
1.35 
(1.20 - 1.52) 
0.77  
(0.67-0.88) 
All cause death (n=640) 1.25 
(1.15-1.36) 
1.42 
(1.29-1.55) 
0.88  
(0.80-0.98) 
MI (n=259) 1.18 
(1.04 - 1.35) 
0.93 
(0.81 - 1.08) 
1.27  
(1.07-1.48) 
CHD (n=812) 1.19 
(1.11 - 1.28) 
1.04 
(0.96 - 1.13) 
1.14  
(1.04-1.25) 
Ischaemic stroke (n=205) 1.39 
(1.21 - 1.60) 
1.22 
(1.04 - 1.43) 
1.15  
(0.97-1.36) 
Heart failure (n=216) 1.86 
(1.66 – 2.08) 
1.69 
(1.43 – 1.98) 
1.10 
(0.93 – 1.31) 
Cancer (n=1078) 0.96 
(0.90 - 1.04) 
1.00 
(0.93 - 1.07) 
0.96  
(0.89-1.04) 
Model adjusted for age, sex, total cholesterol, HDL-cholesterol, systolic blood pressure, cigarettes smoked 
per day, rheumatoid arthritis, diabetes, SIMD score, family history of CVD, use of blood pressure 
medications and use of cholesterol lowering medications.  
* Troponin I: Troponin T ratio 
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Table 3. Association of troponin I and troponin T (per 1SD increase on the log scale) with risk of 
different events, adjusted, with both troponins in the same model 
 
 Troponin I Troponin T  
Hazard ratio 
(95%CI) 
Hazard ratio 
(95%CI) 
CVD (n=1177) 1.23 
(1.15 - 1.32) 
1.02 
(0.94 - 1.09) 
CVD death (n=266) 1.42 
(1.24 - 1.63) 
1.27 
(1.07 - 1.50) 
Non CVD death (n=374) 0.92 
(0.81 - 1.05) 
1.39 
(1.22 - 1.57) 
All cause death (n=640) 1.12 
(1.02-1.23) 
1.35 
(1.22-1.49) 
MI (n=259) 1.26 
(1.09 - 1.45) 
0.85 
(0.73 – 0.99) 
CHD (n=812) 1.21 
(1.12 - 1.31) 
0.96 
(0.88 - 1.05) 
Ischaemic stroke (n=205) 1.36 
(1.17 - 1.59) 
1.07 
(0.90 - 1.27) 
Heart failure (n=216) 1.72 
(1.51 – 1.95) 
1.25 
(1.04 – 1.49) 
Cancer (n=1078) 0.96 
(0.89 - 1.04) 
1.01 
(0.94 - 1.09) 
Model adjusted for age, sex, total cholesterol, HDL-cholesterol, systolic blood pressure, cigarettes 
smoked per day, rheumatoid arthritis, diabetes, SIMD score, family history of CVD, use of blood pressure 
medications, use of cholesterol lowering medications, and each troponin adjusted for the other. 
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Table 4. Lead SNPs, and other SNPs in the same loci, with GWAS significant associations with either troponin (at p< 5X10-8) 
 
Lead SNP Chromosome Position Non-effect 
allele 
Effect 
allele 
Minor allele 
frequency 
P-value Beta Other SNPs Nearest gene 
 
Cardiac troponin I (n=19130) 
rs4253248 4 187155488 G A 0.4871 1.25X10-08 0.050 rs12331618; rs11132382; rs4862669; 
rs2048; rs4253238; rs1912826; 
rs3775298; rs1511801; rs4241815; 
rs4241816; rs4241817; rs4241818; 
rs4253252; rs3733402; rs4253254; 
rs4253255; rs66530140; rs35984397; 
rs4253281; rs4253282; rs1973612; 
rs4253311 
KLKB1, CYP4V2, F11 
rs71483973 10 75900464 A G 0.1679 2.80X10-09 0.072 rs11817132 VCL,AP3M1,ADK 
rs7481951 11 22271870 A T 0.4107 5.77X10-10 0.055 rs12790951; rs4635079; rs4244488; 
rs4244490; rs12807778; rs12290197; 
rs4275631; rs4478991; rs10833711; 
rs10833712; rs4408310; rs10741930; 
rs10833719 
ANO5 
rs148050755 17 62516959 A C 0.0026 3.28X10-11 -0.774 rs187364357; rs138838734 CEP95,SMURF2 
rs2298711 18 57000469 T A 0.1512 9.80X10-12 0.083 rs117153087; rs12604758; 
rs41468947; rs17696641; 
rs12604424; rs12608430; 
rs149168942; rs77905572; 
rs4940867; rs78723480 
CPLX4,LMAN1 
Cardiac Troponin T (n=19127) 
rs16862512 1 169649691 T C 0.0050 3.34X10-08 0.349   C1orf112 
rs548487604 2 85111553 G C 0.0014 9.29X10-09 0.749   TRABD2A 
rs75898208 4 186911043 G A 0.0017 1.69X10-09 0.735   SORBS2 
rs184140292 9 8457116 T C 0.0017 9.84X10-09 0.706   PTPRD 
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Figure Legends 
 
Figure 1. Association of hsTnI and hsTnT unadjusted and adjusted (as per table 2) with the 
composite CVD event. The referent (HR=1) is undetectable levels of hsTnI and hsTnT 
respectively. Both splines on log scale.  
 
Figure 2. Rates of CVD per 1000 person years (n=1,177 events) by low/intermediate/high 
groupings of both cTnI and cTnT. For cTnI: low≤1.8ng/L (n=9426), intermediate 1.9-3.0ng/L 
(n=5052), high≥3.1 ng/L (n=5023). For cTnT: low ≤3.0ng/L (n=9106), intermediate 3.0-5.7ng/L 
(n=5200), high≥5.8 ng/L (n=5195). 
 
Figure 3. Manhattan plots for SNPs associated with hsTnI (a) and hsTnT (b) after adjustment for 
age and sex (n=19,130). The horizontal black dotted line indicates genome-wide significance at 
p<5X10-8, and the horizontal grey dotted line suggestive significance at p<1 X10-5. 
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